Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. Pradofloxacin is a small molecule drug with a maximum clinical trial phase of II that was first approved in 2011. It is grouped under the following drug class(es): Fluoroquinolones, Quinolones and Topoisomerase inhibitors. Its therapeutic use is listed as antibiotics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Veraflox and pradofloxacine. Its PubChem CID is 9802884.
Pradofloxacin
| CAS No | 195532-12-8 |
|---|---|
| Molecular Formula | C21H21FN4O3 |
| Molecular Weight | 396.4 g/mol |
| Synonyms | 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
The listed CAS number is 195532-12-8.
The listed molecular formula is C21H21FN4O3.
The listed molecular weight is 396.4 g/mol.
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid.
The source lists Veraflox and pradofloxacine.